Royalty Pharma PLC
Change company Symbol lookup
Select an option...
RPRX Royalty Pharma PLC
NUE Nucor Corp
MORN Morningstar Inc
TOP TOP Financial Group Ltd
VEEV Veeva Systems Inc
ETY Eaton Vance Tax-Managed Diversified Equity Income Fund
FDX FedEx Corp
TARO Taro Pharmaceutical Industries Ltd
TIO Tingo Group Inc
BEAT Heartbeam Inc
Go

Health Care : Pharmaceuticals | Mid Cap Value
Company profile

Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on more than 35 commercial products, including Vertexs Trikafta, Kalydeco, Orkambi and Symdeko, Biogens Tysabri, AbbVie and Johnson & Johnsons Imbruvica, Astellas and Pfizer's Xtandi, GSKs Trelegy, Novartis Promacta, Pfizer's Nurtec ODT, Johnson & Johnsons Tremfya, Roches Evrysdi, Gilead's Trodelvy, and 12 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Olpasiran, Omecamtiv mecarbil, Pelabresib, Pelacarsen, Seltorexant, Trontinemab, Tulmimetostat and Zavegepant. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.

Postmarket

Last Trade
Delayed
$32.65
0.14 (0.43%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$32.51
Day's Change
0.13 (0.40%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
32.77
Day's Low
32.17
Volume
(Heavy Day)
Volume:
2,800,636

10-day average volume:
2,252,930
2,800,636

Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.